Log In
BCIQ
Print this Print this
 

Hemangeol, Hemangiol, propranolol

  Manage Alerts
Collapse Summary General Information
Company Laboratoires Pierre Fabre S.A.
DescriptionPediatric formulation of propranolol, a non-selective adrenergic receptor beta (ADRB) blocker
Molecular Target Adrenergic receptor beta (ADRB)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard Indication Cancer (unspecified)
Indication DetailsTreat infantile hemangiomas
Regulatory Designation EU - Standard Review (Treat infantile hemangiomas);
Japan - Orphan Drug (Treat infantile hemangiomas);
Australia - Orphan Drug (Treat infantile hemangiomas)
PartnerMaruho Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/21/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today